S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
Judge revives Obama-era ban on coal sales from federal lands
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:STIM

Neuronetics - STIM Stock Forecast, Price & News

$4.46
-0.01 (-0.22%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.38
$4.52
50-Day Range
$2.92
$4.66
52-Week Range
$1.98
$8.88
Volume
120,343 shs
Average Volume
1.64 million shs
Market Capitalization
$120.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Neuronetics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
135.4% Upside
$10.50 Price Target
Short Interest
Healthy
2.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Neuronetics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Growing
From ($1.65) to ($1.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

489th out of 1,117 stocks

Surgical & Medical Instruments Industry

52nd out of 113 stocks

STIM stock logo

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics Stock Performance

NASDAQ:STIM traded down $0.01 during trading on Friday, reaching $4.46. 120,343 shares of the company's stock were exchanged, compared to its average volume of 422,742. The company has a debt-to-equity ratio of 0.46, a current ratio of 5.02 and a quick ratio of 4.64. The business has a 50 day moving average price of $3.67 and a 200-day moving average price of $3.20. The stock has a market capitalization of $120.52 million, a P/E ratio of -3.19 and a beta of 2.09. Neuronetics has a fifty-two week low of $1.98 and a fifty-two week high of $8.88.

Neuronetics (NASDAQ:STIM - Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.41) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.41). Neuronetics had a negative return on equity of 46.12% and a negative net margin of 62.44%. The business had revenue of $14.18 million for the quarter, compared to analyst estimates of $13.20 million. During the same period in the previous year, the firm earned ($0.31) EPS. Sell-side analysts forecast that Neuronetics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Neuronetics

In related news, major shareholder Cannell Capital Llc acquired 15,369 shares of the firm's stock in a transaction on Friday, May 20th. The shares were purchased at an average cost of $2.41 per share, for a total transaction of $37,039.29. Following the completion of the acquisition, the insider now directly owns 3,393,063 shares in the company, valued at $8,177,281.83. The purchase was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Keith J. Sullivan sold 63,466 shares of the stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $3.72, for a total transaction of $236,093.52. Following the transaction, the chief executive officer now owns 850,999 shares in the company, valued at $3,165,716.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Cannell Capital Llc purchased 15,369 shares of the company's stock in a transaction that occurred on Friday, May 20th. The shares were purchased at an average cost of $2.41 per share, with a total value of $37,039.29. Following the completion of the acquisition, the insider now owns 3,393,063 shares in the company, valued at approximately $8,177,281.83. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 110,632 shares of company stock valued at $275,932 and sold 79,533 shares valued at $293,135. Insiders own 5.20% of the company's stock.

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Stock News Headlines

Recap: Neuronetics Q2 Earnings - Benzinga
Neuronetics's Earnings: A Preview - Benzinga
Read Why Neuronetics Shares Are Trading Higher Today
See More Headlines
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Company Calendar

Last Earnings
11/09/2021
Today
8/13/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STIM
Employees
175
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+135.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-31,190,000.00
Pretax Margin
-62.44%

Debt

Sales & Book Value

Annual Sales
$55.31 million
Book Value
$2.53 per share

Miscellaneous

Free Float
25,618,000
Market Cap
$120.51 million
Optionable
Not Optionable
Beta
2.09














STIM Stock - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" STIM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STIM, but not buy additional shares or sell existing shares.
View STIM analyst ratings
or view top-rated stocks.

What is Neuronetics' stock price forecast for 2022?

3 equities research analysts have issued 12 month price targets for Neuronetics' shares. Their STIM share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 135.4% from the stock's current price.
View analysts price targets for STIM
or view top-rated stocks among Wall Street analysts.

How have STIM shares performed in 2022?

Neuronetics' stock was trading at $4.46 at the beginning of the year. Since then, STIM stock has increased by 0.0% and is now trading at $4.46.
View the best growth stocks for 2022 here
.

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our STIM earnings forecast
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.80 million. Neuronetics had a negative trailing twelve-month return on equity of 46.12% and a negative net margin of 62.44%. During the same quarter last year, the business posted ($0.18) EPS.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14.50 million-$15.50 million, compared to the consensus revenue estimate of $14.85 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Millrace Asset Group Inc. (2.36%), Brandywine Global Investment Management LLC (1.58%), Premier Fund Managers Ltd (1.12%), Allspring Global Investments Holdings LLC (0.85%), Envestnet Asset Management Inc. (0.40%) and Renaissance Technologies LLC (0.32%). Insiders that own company stock include Brian E Farley, Bruce Joseph Shook, Cannell Capital Llc, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong, Stephen M Campe and William Andrew Macan.
View institutional ownership trends
.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $4.46.

How much money does Neuronetics make?

Neuronetics (NASDAQ:STIM) has a market capitalization of $120.52 million and generates $55.31 million in revenue each year. The company earns $-31,190,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Neuronetics have?

The company employs 175 workers across the globe.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.

This page (NASDAQ:STIM) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.